Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RYZ101 in refractory and relapsing multiple myeloma
NCT06411301Phase 1Withdrawn
- Sponsor
- Institut Jules Bordet
- Start
- Oct 2024
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of actinium-225 dotatate in multiple myeloma (MM), sponsored by Institut Jules Bordet. Primary endpoints: Safety and tolerability of 225Ac-DOTATATE at 84 days and Recommended phase II dose of 225Ac-DOTATATE at 84 days. Planned start Oct 2024; status: withdrawn.
02
Drugs
actinium-225 dotatate
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06411301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06411301.